Will State Action on Biosimilars Thwart Anticipated Savings for Health Care Programs

Mintz Levin attorneys Ellyn Sternfield, Theresa Carnegie, and Joanne Hawana will be presenting a Bloomberg BNA Webinar entitled, "Will State Action on Biosimilars Thwart Anticipated Savings for Health Care Programs?" on August 5th. They discuss the state action on biosimilars, potential cost savings for Health Care Programs, the role of the FDA, and the CMS guidance addressing Medicare and Medicaid coverage and reimbursement of FDA-approved biosimilar drug products.

Educational Objectives:

• Discuss the state action on biosimilars
• Explore potential cost savings for health care programs
• Address the role of the Federal Drug Administration’s approval of biosimilar drug products
• Review the Centers for Medicare and Medicaid services guidance addressing Medicare and Medicaid coverage and reimbursement of FDA-approved biosimilar drug products